DOVATO is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.[1]

DOVATO vs. BIC/FTC/TAF       Why start with DOVATO?       Your DOVATO patients

The first head-to-head RCT of DOVATO vs. BIC/FTC/TAF in a naïve to treatment population[2]

VOGUE is a phase IIIb, randomised, open‑label, non‑inferiority study assessing the efficacy and safety of DOVATO (n=254) vs. BIC/FTC/TAF (n=255).[2]

Proven non‑inferior efficacy vs. BIC/FTC/TAF in naïve to treatment participants[2]

At Week 48, 89% of participants receiving DOVATO achieved viral suppression (HIV-1 RNA <50 copies/mL), demonstrating non-inferior efficacy vs. BIC/FTC/TAF (92%), including in participants with baseline viral load ≥100,000 copies/mL (85% vs. 89%).[2]
Proportion of participants with HIV-1 RNA <50 copies/mL at Week 48

(Primary endpoint analysis: FDA Snapshot algorithm; -10% non-inferiority margin)[2]

Adapted from Ghosn J et al. 2026.[2]

0 cases of treatment emergent resistance with DOVATO (n=0/254) vs. 0 (n=0/255) with BIC/FTC/TAF at Week 48*,[2]

4.1 weeks was the median time to viral suppression with DOVATO, which was comparable to BIC/FTC/TAF[2]

(DOVATO: 4.1 weeks; 95% CI: 4.1, 4.1; BIC/FTC/TAF: 4.1 weeks; 95% CI, 4.1, 4.3; after adjustment for baseline viral load and CD4+ T-cell category the hazard ratio was 1.23 (95% CI, 1.03; 1.47)[2]

Participants were allowed to rapidly start treatment, even when no resistance testing results were available at baseline[2]

The safety profile of DOVATO was comparable to BIC/FTC/TAF through Week 48, with no new safety signals identified:

  • 0% of participants experienced treatment‑related AEs leading to discontinuation with DOVATO (n=0/254) vs. 0.8% with BIC/FTC/TAF (n=2/255)†,[2]
  • 1.2% of participants experienced any AEs leading to discontinuation with DOVATO (n=3/254) and BIC/FTC/TAF (n=3/255)[2]

Treat Ahead from the start with DOVATO[1–3]

~150 people every hour were newly diagnosed with HIV globally in 2024.[4] DOVATO has shown proven efficacy in newly diagnosed people living with HIV.[1–3,5–7]

Proven viral suppression across diverse naïve to treatment people living with HIV, including vs. BIC/FTC/TAF[2,3,7,9,10]

Demonstrated across 6 RCTs and a systematic literature review of real-world evidence[2,3,5,7,9,10]

4 guidelines (DHHS, EACS, IAS, WHO) recommend DOVATO for newly diagnosed people living with HIV[11–14]

Support your naïve to treatment patients now and for the future[2,3,7,9,10]

People living with HIV are living longer than ever before.[15] That is why it is important to recognise and consider the challenges that may impact them now and in the future.[2,3,7,9,10]

Presenting with a high viral load and unknown baseline resistance

Presenting with a very high viral load in a test-and-treat setting

Presenting with a high viral load and hypertension

Presenting with low CD4+ T-cell count and additional health concerns

Proven Efficacy.
High Barrier to Resistance.
Fewer medicines vs. 3-drug regimens.[1–3]

* Among the 14 participants meeting CVW criteria, resistance data were obtained for 6 participants (DOVATO, n=2; BIC/FTC/TAF, n=4) and no treatment-emergent resistance to INSTIs or NRTIs was identified. For the remaining 8 participants (DOVATO, n=5; BIC/FTC/TAF, n=3) , resistance testing failed due to the VL of samples being below the assay cutoff.[2]

† Treatment-related AE leading to discontinuation with BIC/FTC/TAF included weight increase (n=1) and alopecia (n=1).[2]

‡ Resistance-associated mutations (RAMs) at screening were reviewed once results became available (approximately Week 4). Participants with major resistance-associated mutations to INSTIs, 3TC, FTC, or TAF were required to discontinue study treatment.[2]
§ Participants with immunity to HBV, including those with isolated hepatitis B core antibody positivity without detectable HBV DNA were not excluded.[2]

AE, adverse event; ART, antiretroviral therapy; BIC, bictegravir; BL, baseline; CI, confidence interval; CVW, confirmed virologic withdrawal; DDI, drug-drug interaction; DHHS, Department of Health and Human Services; EACS, European AIDS Clinical Society; FDA, United States Food and Drug Administration; FTC, emtricitabine; HBV, Hepatitis B Virus; IAS, International Antiviral Society; INSTI, integrase strand transfer inhibitor; ITT, intention-to-treat; NRTI, nucleoside reverse transcriptase inhibitor; RCT, randomised controlled trial; TAF, tenofovir alafenamide; VL, viral load; WHO, World Health Organisation.

References:

  1. DOVATO (dolutegravir/lamivudine) Summary Product of Characteristics (SmPC)
  2. Ghosn J et al. Slides presented at AIDS. 26-31 July 2026. Rio de Janeiro, Brazil, OAB0106LB.
  3. Cahn P et al. AIDS 2022; 36(1): 39–48.
  4. Executive summary — UNAIDS. 2025 Global AIDS Update — AIDS, Crisis and the Power to Transform. Available at: Executive summary. Available at: https://www.unaids.org/en/resources/documents/2025/2025-global-aids-update-summary. Accessed October 2026.
  5. Fraysse J et al. Infect Dis Ther. 2025; 14(2): 357–383.
  6. Lazarus J et al. HIV Med. 2023; 24: 8–19. (Suppl Appendix 2).
  7. Figueroa M et al. Clin Infect Dis 2026; 82(1): 122–131.
  8. Figueroa M et al. Slides presented at HIV Glasgow. 10–13 November 2024. Glasgow, UK. 024.
  9. Cordova E et al. Lancet HIV 2025; 12(2): 1–10.
  10. Rolle C et al. Open Forum Infect Dis 2023; 10(3): ofad101.
  11. Department of Health and Human Services (DHSS). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. September 2026.
  12. Gandhi R et al. JAMA 2025; 333(7): 609–628.
  13. ̌European AIDS Clinical Society (EACS) Guidelines. Version 13.0. October 2025.
  14. World Health Organisation. Recommendations on first- and second-line antiretroviral regimens. July 2019.
  15. Trickey A et al. Lancet HIV 2023; 10(5): e295–e307.

PM-GB-DLL-WCNT-250004 V2 | October 2026

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.